Analyzing Current Long COVID Treatments
Many physicians actively evaluate various Long COVID treatments to support patients suffering from persistent fatigue and cognitive issues. Consequently, researchers recently conducted a double-blind, randomized clinical trial to test common medications. The study specifically investigated metformin and ursodeoxycholic acid (UDCA). However, the findings suggest these drugs do not provide significant clinical benefits for postacute sequelae of COVID-19. Therefore, clinicians must remain cautious when considering off-label prescriptions for these specific indications.
The Study Design and Outcomes
Researchers recruited 396 adults with significant persistent symptoms for this trial. These participants received either oral metformin, UDCA, or a double placebo for a 14-day period. Notably, the team used the PASC index score to measure recovery and symptom improvement. After eight weeks, the data showed no meaningful difference between the treatment groups and the placebo group. Specifically, recovery rates remained statistically similar across all three arms of the study. This result indicates that neither drug effectively alters the course of the illness once it becomes chronic.
Clinical Guidance for Indian Practitioners
Medical professionals in India face a high volume of patients seeking effective Long COVID treatments. While previous studies suggested metformin might reduce the risk of developing long-term symptoms if taken during the acute phase, this new evidence clarifies its role. Specifically, the drug does not appear to treat established symptoms effectively. Practitioners should focus on multidisciplinary care and symptomatic management instead. Furthermore, they should monitor evolving guidelines from the Ministry of Health and Family Welfare. Consequently, evidence-based rehabilitation remains the cornerstone of care for these complex cases.
Frequently Asked Questions
Q1: Did metformin show any benefit in preventing Long COVID in earlier studies?
Yes, some previous research indicated that taking metformin during the acute phase of a COVID-19 infection could reduce the risk of developing PASC. However, this new trial confirms it does not help patients who already have established Long COVID symptoms.
Q2: Is ursodeoxycholic acid (UDCA) recommended for PASC symptoms?
Based on this randomized clinical trial, UDCA did not improve recovery or symptoms compared to a placebo. Therefore, doctors should not routinely prescribe UDCA for the treatment of Long COVID symptoms.
Q3: What should Indian doctors focus on for Long COVID management?
Physicians should prioritize symptomatic relief, physical rehabilitation, and addressing specific organ complications. Currently, no single pharmacological treatment is proven to cure the entire spectrum of PASC symptoms.
References
- Lim SY et al. Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial. Ann Intern Med. 2026 Mar 03. doi: 10.7326/ANNALS-25-04883. PMID: 41771135.
- Medical Dialogues. Metformin and ursodeoxycholic acid both fail to improve long COVID recovery in new clinical trial. March 03, 2026.
- Ministry of Health and Family Welfare, Government of India. National Comprehensive Guidelines for Management of Post-COVID Sequelae.
“